This is the first commercial use of the AI-based Clinical Decision Support System for diabetes since receiving the FDA clearance three weeks ago
TEL AVIV, Israel, October 20, 2021--(BUSINESS WIRE)--DreaMed Diabetes AI LTD. ("DreaMed" or the "Company"), a developer of the Advisor Pro Al Clinical Decision Support platform for diabetes, announced today it deployed its DreaMed’s Advisor Pro - a digital diabetes management platform in one of the top 10 metropolitan U.S. children's hospital1.
Advisor Pro by DreaMed is an Al Clinical Decision Support System for diabetes, providing remote insulin management with data analysis and therapy management tools. The solution was deployed at the hospital together with existing diabetes management protocols so patients can receive a personalized, precise, and effective diabetes treatment.
In the United States alone, 34.2 million people—just over 1 in 10—have diabetes. When it comes to youth diabetes, according to American Diabetes Association, about 210,000 Americans under age 20 are estimated to have been diagnosed with diabetes.
Advisor Pro is the first decision support system to receive FDA clearances for Type 1 and Type 2 diabetes treatments – for pediatrics and adults. The solution leverages AI to optimize insulin administration and assist healthcare providers in caring for diabetes patients who use insulin pumps or injections and monitor their glucose.
"I am thrilled to see DreaMed being used by providers and patients so soon after the recent FDA clearance," says Eran Atlas, Founder, and CEO of DreaMed Diabetes. "Our first FDA clearance, which was for our Type 1 insulin pump solution, led to partnerships with leading diabetes treatment centers including Yale-New Haven Health, Texas Children's Hospital, and the University of Florida."
"Our fourth FDA clearance for our Type 1 & Type 2 solution on insulin injections opened the door to deeper collaborations with top-tier children's hospitals to improve their diabetes management program for a much larger portion their paitent pannel. Our goal is to help people of all ages manage their diabetes optimally and achieve sustainable health improvement. I'm truly excited that a growing number of healthcare practitioners and their patients can benefit from our solution."
About DreaMed Diabetes
DreaMed Diabetes is a medical device company providing personalized diabetes treatment optimization solutions. The company was established in 2014 and commercialized its first product, GlucoSitter, an artificial pancreas technology licensed to Medtronic Diabetes. Since then, DreaMed Diabetes has been vigorously working on the DreaMed Advisor portfolio, decision support tools in diabetes management. DreaMed became the first and only company in the world to receive a CE Mark and FDA clearance for DreaMed Advisor Pro, a decision support system in Type I diabetes patients using data from CGM/SMBG and insulin pumps. The company continues developing the DreaMed Advisor portfolio, which will aid all people living with diabetes no matter the insulin therapy or diabetes type and their healthcare professionals to provide personalized insulin therapy. For more information, please visit https://dreamed-diabetes.com/
1 According to U.S. News ranks for children's hospitals for diabetes & endocrinology in the U.S.A
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005690/en/